TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18058838

Group type: EXPERIMENTAL
Intervention: Memantine 20 mg/day
Number of subjects: 1826

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1826
Study: 17310957

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: No statin (control)
Number of subjects: 70
Study: 12942493

Group type: EXPERIMENTAL
Intervention: Aspirin 150 mg per day
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study: 10773510

Group type: EXPERIMENTAL
Intervention: Topical anesthesia (TA)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Combined peribulbar and retrobulbar block (PRBB)
Number of subjects: 98
Study: 8850771

Group type: EXPERIMENTAL
Intervention: Dinner music (soothing music)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dinner music
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control period (no music)
Number of subjects: 5
Study: 1498266

Group type: EXPERIMENTAL
Intervention: 150 mg diclofenac hydrogel bead (HGB) capsule after a standardized breakfast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 150 mg diclofenac hydrogel bead (HGB) capsule under fasted conditions
Number of subjects: 12
Study: 6656559

Group type: EXPERIMENTAL
Intervention: Higher Intensity (HI) training at 60-75% HRR (N = 14)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lower Intensity (LI) training at 30-45% HRR (N = 14)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (non-exercising volunteers)
Number of subjects: 32
Study: 30865171

Group type: EXPERIMENTAL
Intervention: Religiosity (measured by 7-item Religious Beliefs and Behaviors survey)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: HIV-related stigma (measured by Stigma Scale for Chronic Illness)
Number of subjects: 226
Study: 28512171

Group type: EXPERIMENTAL
Intervention: Congruent PWLs
Number of subjects: 120

Group type: COMPARATOR
Intervention: Incongruent PWLs
Number of subjects: 120
Study: 26116561

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) group program
Number of subjects: 128

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 128
Study: 24070367

Group type: EXPERIMENTAL
Intervention: bimatoprost 0.01%
Number of subjects: 40

Group type: COMPARATOR
Intervention: travoprost/timolol
Number of subjects: 40
Study: 22033542

Group type: EXPERIMENTAL
Intervention: Doppler-guided hemorrhoidal artery ligation followed by ligation and mucopexy (DSL)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Suture ligation of hemorrhoids (SL)
Number of subjects: 48
Study: 20051618

Group type: EXPERIMENTAL
Intervention: Wobble board exercises for six weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Baseline treatment programs (Control)
Number of subjects: 17
Study: 16854948

Group type: EXPERIMENTAL
Intervention: Randomised controlled trials
Number of subjects: 260

Group type: COMPARATOR
Intervention: Cohort studies
Number of subjects: 260

Group type: COMPARATOR
Intervention: Case-control studies
Number of subjects: 260

Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 260

Group type: COMPARATOR
Intervention: Cohort studies and case-control studies
Number of subjects: 260
Study: 15505888

Group type: EXPERIMENTAL
Intervention: Conditional mixed models adjusting for non-ignorable drop-out
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maximum likelihood approach assuming ignorable drop-out
Number of subjects: 0
Study: 11558858

Group type: EXPERIMENTAL
Intervention: Losartan monotherapy (50 to 150 mg)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Losartan/HCTZ (50/0 to 50/12.5 to 100/25 mg)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study: 9755543

Group type: EXPERIMENTAL
Intervention: salmeterol 50 mg twice a day
Number of subjects: 60

Group type: COMPARATOR
Intervention: salbutamol 200 mg four times a day
Number of subjects: 60
Study: 8071510

Group type: EXPERIMENTAL
Intervention: Right lateral decubitus position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Left lateral decubitus position
Number of subjects: 20
Study: 2838318

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31485804

Group type: EXPERIMENTAL
Intervention: Betaine hydrochloride (BHCl) 4500 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: No acid supplementation
Number of subjects: 9
Study: 29248014

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI) - SC PMTCT plus 'Protect Your Family' intervention; 6 CHCs; n=342
Number of subjects: 699

Group type: COMPARATOR
Intervention: Standard Care (SC) - standard care condition plus time-equivalent attention-control; 6 CHCs; n=357
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 699

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 699
Study: 26056249

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radial access
Number of subjects: 0

Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 0
Study: 23801579

Group type: EXPERIMENTAL
Intervention: Teplizumab (14-day full-dose)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Teplizumab
Number of subjects: 516

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 516
Study: 21597220

Group type: EXPERIMENTAL
Intervention: G1: HF 9.6%+Silane+Panavia F2.0
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: G2: HF 9.6%+Silane+HT+Panavia F2.0
Number of subjects: 32

Group type: COMPARATOR
Intervention: G3: Silane+HT+Panavia F2.0
Number of subjects: 32

Group type: COMPARATOR
Intervention: G4: Silane+Panavia F2.0
Number of subjects: 32
Study: 19336502

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg) added to aspirin
Number of subjects: 7554

Group type: COMPARATOR
Intervention: Placebo added to aspirin
Number of subjects: 7554
Study: 16955299

Group type: EXPERIMENTAL
Intervention: Active and passive extension immediately after ACL reconstruction (Group A, n=11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No active and passive extension immediately after ACL reconstruction (Group B, n=11)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 22
Study: 15330214

Group type: EXPERIMENTAL
Intervention: BVM (bleomycin, vincristine, methotrexate)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: BVM and mitolactol (dibromodulcitol)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: BVM and cisplatin
Number of subjects: 80

Group type: COMPARATOR
Intervention: BVM alone (Group N)
Number of subjects: 80
Study: 10873076

Group type: EXPERIMENTAL
Intervention: Idoxifene 40 mg/day for 14-21 days
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Idoxifene
Number of subjects: 77
Study: 9296417

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CSEA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Epidural anesthesia (EA)
Number of subjects: 120
Study: 8296487

Group type: EXPERIMENTAL
Intervention: Thymostimulin treatment (6 subjects)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (7 subjects, untreated)
Number of subjects: 13
Study: 3113973

Group type: EXPERIMENTAL
Intervention: 10 mg X kg‐1 once daily for 3 days
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 5 mg X kg‐1 thrice daily for one day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 7.5 mg X kg‐1 thrice daily for one day
Number of subjects: 46
Study: 29445116

Group type: EXPERIMENTAL
Intervention: 3D heads-up microscope (3DM) during 25-gauge pars plana vitrectomy (PPV)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional ophthalmic microscope (TM) during 25-gauge pars plana vitrectomy (PPV)
Number of subjects: 50
Study: 26295565

Group type: EXPERIMENTAL
Intervention: Intralesional PPD antigen
Number of subjects: 69

Group type: COMPARATOR
Intervention: Intralesional saline (placebo)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 69
Study: 23820295

Group type: EXPERIMENTAL
Intervention: Walkaround (body postural support)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (conventional means: cane, therapist)
Number of subjects: 22
Study: 22690198

Group type: EXPERIMENTAL
Intervention: Nutrition educational program delivered by trained classroom teachers
Number of subjects: 464
Study: 20868279

Group type: EXPERIMENTAL
Intervention: Full-dose nevirapine (FD)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Dose escalation (DE) nevirapine
Number of subjects: 211
Study: 18778120

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 320/9 microg
Number of subjects: 1704

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 160/9 microg
Number of subjects: 1704

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI (both dosages)
Number of subjects: 1704

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 320/9 microg
Number of subjects: 1704

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/9 microg
Number of subjects: 1704

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 1704
Study: 17119047

Group type: EXPERIMENTAL
Intervention: Nurse-administered intervention consisting of cognitive behavioral therapy and medications
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse-administered intervention and Usual care
Number of subjects: 0
Study: 14624421

Group type: EXPERIMENTAL
Intervention: Acetylcysteine 600 mg b.i.d. (five doses)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 10966533

Group type: EXPERIMENTAL
Intervention: Negative baseline myoglobin assay
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Positive baseline myoglobin assay
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Complete ST resolution (>/=70%)
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Partial ST resolution (30% to <70%)
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: No ST resolution (<30%)
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Negative myoglobin assay and complete ST resolution
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Positive myoglobin assay or ST resolution <70%
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Positive myoglobin assay and ST resolution <70%
Number of subjects: 2079
Study: 8858434

Group type: EXPERIMENTAL
Intervention: Preparatory information (procedural, sensory, and coping information) plus written information
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (routine advice and support from ward, medical and nursing staff)
Number of subjects: 82
Study: 7699420

Group type: EXPERIMENTAL
Intervention: 'eight‐drugs‐in‐one‐day' chemotherapy regimen
Number of subjects: 130
Study: 2954253

Group type: EXPERIMENTAL
Intervention: Pirprofen (1200 mg daily)
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Pirprofen (800 mg daily)
Number of subjects: 562

Group type: COMPARATOR
Intervention: Piroxicam (20 mg)
Number of subjects: 562

Group type: COMPARATOR
Intervention: Naproxen (1000 mg)
Number of subjects: 562
Study: 29282574

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 79

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both surgical techniques
Number of subjects: 79
Study: 27697758

Group type: EXPERIMENTAL
Intervention: Tafenoquine (300 mg) plus dihydroartemisinin-piperaquine (120 mg/960 mg for 36 to <75 kg; 160 mg/1,280 mg for ≥75 to 100 kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tafenoquine (300 mg) plus artemether-lumefantrine (80 mg/480 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tafenoquine alone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine alone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Artemether-lumefantrine alone
Number of subjects: 120
Study: 25640275

Group type: EXPERIMENTAL
Intervention: Electronic patient-reported outcomes system
Number of subjects: 104
Study: 24241095

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (oral capsule, 3 g/d)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 21146844

Group type: EXPERIMENTAL
Intervention: Early oral feeding (liquid diet on postoperative day 2, soft diet from day 3 until discharge)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (liquid diet on postoperative day 4)
Number of subjects: 54
Study: 18356328

Group type: EXPERIMENTAL
Intervention: Evening meals with barley kernel based bread (ordinary, high‐amylose‐ or beta‐glucan‐rich genotypes)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Evening meal with white wheat flour bread (WWB) enriched with a mixture of barley fiber and resistant starch
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Evening meal with barley‐kernel bread
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Breath hydrogen
Number of subjects: 15
Study: 16555338

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC+ group)
Number of subjects: 47
Study: 14728106

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 10881255

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (oral Premarin 0.625 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7604069

Group type: EXPERIMENTAL
Intervention: Theophylline effervescent tablet (Euphyllin quick 200)
Number of subjects: 12
Study: 2232062

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 13
Study: 209490

Group type: EXPERIMENTAL
Intervention: Physostigmine (1.0mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31577981

Group type: EXPERIMENTAL
Intervention: Deliberate emotion regulation interpersonal scaffolding
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study: 28555502

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum subsp. infantis R0033
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum R0071
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Lactobacillus helveticus R0052
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 25876740

Group type: EXPERIMENTAL
Intervention: CR+G (genetic test results and counseling)
Number of subjects: 601

Group type: COMPARATOR
Intervention: CR+EYE (control eye disease counseling)
Number of subjects: 601
Study: 23261023

Group type: EXPERIMENTAL
Intervention: Adhesive strips
Number of subjects: 82

Group type: COMPARATOR
Intervention: Absorbable sutures (control)
Number of subjects: 82
Study: 20473862

Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 306

Group type: COMPARATOR
Intervention: FOLFOX-6
Number of subjects: 306
Study: 19657901

Group type: EXPERIMENTAL
Intervention: Power Breathing program
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 16912619

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg PO betamethasone
Number of subjects: 52

Group type: COMPARATOR
Intervention: 0.6 mg/kg IM dexamethasone
Number of subjects: 52
Study: 14993491

Group type: EXPERIMENTAL
Intervention: Super-flux polysulfone (F 500S)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-flux polysulfone (F 60S)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Super-flux cellulose-tri-acetate (Tricea 150G)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-flux polysulfone (PS: F 6HPS)
Number of subjects: 10
Study: 11732958

Group type: EXPERIMENTAL
Intervention: Routine TST placement with physician-to-school nurse communication
Number of subjects: 134

Group type: COMPARATOR
Intervention: Routine TST placement with no physician-to-school nurse communication (Control)
Number of subjects: 134
Study: 9142556

Group type: EXPERIMENTAL
Intervention: Right-nostril breathing
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Left-nostril breathing
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Alternate-nostril breathing
Number of subjects: 130

Group type: COMPARATOR
Intervention: Breath awareness
Number of subjects: 130

Group type: COMPARATOR
Intervention: Practice of mudras
Number of subjects: 130
Study: 8070785

Group type: EXPERIMENTAL
Intervention: Intravenous amino acids infusion
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Intra-amniotic amino acids infusion
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 2853749

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study: 31592728

Group type: EXPERIMENTAL
Intervention: Pharmacomechanical catheter-directed thrombolysis (PCDT) plus anticoagulation
Number of subjects: 692

Group type: COMPARATOR
Intervention: Standard treatment with anticoagulation alone
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Pharmacomechanical catheter-directed thrombolysis (PCDT) for iliofemoral DVT
Number of subjects: 692

Group type: COMPARATOR
Intervention: Standard therapy for femoral-popliteal DVT
Number of subjects: 692
Study: 28624307

Group type: COMPARATOR
Intervention: Hexavac
Number of subjects: 751

Group type: COMPARATOR
Intervention: Infanrix hexa
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: HBVaxPro challenge dose
Number of subjects: 751
Study: 26241077

Group type: EXPERIMENTAL
Intervention: Low-tidal volume ventilation (6 ml/kg predicted body weight)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual care ventilation (10 ml/kg)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Low-tidal volume ventilation
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual care ventilation
Number of subjects: 128
Study: 24050942

Group type: EXPERIMENTAL
Intervention: Experimental medications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subgroup analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factors associated with adherence
Number of subjects: 0
Study: 21144559

Group type: EXPERIMENTAL
Intervention: CA-125+
Number of subjects: 39105

Group type: EXPERIMENTAL
Intervention: TVU+
Number of subjects: 39105

Group type: EXPERIMENTAL
Intervention: CA-125+/TVU+
Number of subjects: 39105
Study: 19803539

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 IV infusion every 21 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pac3w (Paclitaxel 175 mg/m2 IV infusion every 21 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pac1w (Paclitaxel administered in 1-week cycles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nab-P (nano albumin-bound paclitaxel given every 3 weeks)
Number of subjects: 0
Study: 16856902

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing within 2 consecutive days (FRP)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Three one‐stage, full‐mouth disinfection protocols (FM) applying antiseptics
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Chlorhexidine for 2 months (FMCHX)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride for 2 months (FMF)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Chlorhexidine for 2 months followed by amine fluoride/stannous fluoride for another 6 months (FMCHX+F)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Scaling and root planing, quadrant by quadrant, at two‐week intervals (negative control, NC)
Number of subjects: 71
Study: 12904192

Group type: EXPERIMENTAL
Intervention: Prilocaine-ropivacaine (PR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Saline-ropivacaine (SR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline-saline (SS)
Number of subjects: 40
Study: 10981242

Group type: EXPERIMENTAL
Intervention: Cefepime 2 g every eight hours
Number of subjects: 276

Group type: COMPARATOR
Intervention: Ceftazidime 2 g every eight hours
Number of subjects: 276
Study: 8956793

Group type: EXPERIMENTAL
Intervention: Rb expression
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Rb and E‐cadherin expression
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Rb and myc expression
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Amount of eosinophilic and lymphocytic infiltrates
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Amount of lymphocytic infiltrate
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: TNM stage (I + II) and marked lymphocytic infiltrate
Number of subjects: 105
Study: 1526693

Group type: EXPERIMENTAL
Intervention: Tilidine-naloxone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pentazocine
Number of subjects: 50
Study: 6419574

Group type: EXPERIMENTAL
Intervention: Oral sustained-release nitroglycerin (SRNG, 6.5 mg)
Number of subjects: 46
Study: 30615058

Group type: EXPERIMENTAL
Intervention: Higher triglycerides (TG) ≥150 mg/dl
Number of subjects: 12549

Group type: EXPERIMENTAL
Intervention: Higher TG:HDL-C ratio ≥2.7
Number of subjects: 12549

Group type: EXPERIMENTAL
Intervention: Lower total cholesterol (TC) ≥200 mg/dl
Number of subjects: 12549

Group type: EXPERIMENTAL
Intervention: Lower low-density lipoprotein cholesterol (LDL-C) ≥130 mg/dl
Number of subjects: 12549
Study: 29373094

Group type: EXPERIMENTAL
Intervention: SB3 (trastuzumab biosimilar)
Number of subjects: 800

Group type: COMPARATOR
Intervention: TRZ (reference trastuzumab)
Number of subjects: 800
Study: 27179795

Group type: EXPERIMENTAL
Intervention: Combined strength and speed endurance training (CSS; n = 9)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (CON; n = 7)
Number of subjects: 16
Study: 24193112

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 605

Group type: COMPARATOR
Intervention: Control group (EM)
Number of subjects: 605
Study: 21410100

Group type: EXPERIMENTAL
Intervention: Functional pain control infusion pump
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo pain control infusion pump
Number of subjects: 24
Study: 19617576

Group type: EXPERIMENTAL
Intervention: Elevated factor IX levels
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: Elevated factor XI levels
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Factor XII deficiency
Number of subjects: 1489